Clik here to view.
Isotechnika releases shareholder letter
In a letter to shareholders issued today, Isotechnika Pharma (TSX:ISA) CEO Dr. Robert Foster explains the company’s decision to move its voclosporin drug into Phase 3 clinical trials for the prevention...
View ArticleClik here to view.
Navidea presents Lymphoseek Phase 3 data
Data from a Phase 3 clinical study by Navidea Biopharmaceuticals (AMEX:NAVB), investigating 99m-Tc-Tilmanocept (Lymphoseek) in oral and squamous cell cancers, were presented as a poster presentation at...
View ArticleClik here to view.
Navidea presents Lymphoseek data
Navidea Biopharmaceuticals (AMEX:NAVB) has presented data from a meta-analysis comparing 99m-Tc-Tilmanocept (Lymphoseek) to sulfur colloid at a session of the Sentinel Node Oncology Foundation and...
View ArticleClik here to view.
C. K. Cooper starts Pozen at buy
C.K. Cooper has initiated coverage of Pozen (NASDAQ:POZN) with a “buy” rating and $11 price target based on the “potential value we expect Pozen to derive from a marketing agreement and FDA approval of...
View ArticleClik here to view.
Isotechnika partner completes enrolment in Phase 3 uveitis study
Isotechnika Pharma (TSX:ISA) partner, Lux Biosciences, has completed patient enrolment in its Phase 3 clinical study using voclosporin (branded as Luveniq) for the treatment of non-infectious uveitis,...
View ArticleClik here to view.
Trimel completes Phase 3 CompleoTRT efficacy trial
All patients have been dosed in the efficacy portion of Trimel Pharmaceuticals’ (TSX:TRL) CompleoTRT Phase 3 clinical trial for the treatment of male hypogonadism or “Low T”. Efficacy results are...
View ArticleClik here to view.
Actinium Pharma begins manufacturing of BC8
Actinium Pharmaceuticals (NYSE MKT:ATNM) has initiated manufacturing of the Phase 3 clinical lot of BC8, a novel murine monoclonal antibody, which is conjugated with iodine-131 radioisotope to form...
View ArticleClik here to view.
Braeburn resubmits NDA for Titan Pharma’s Probuphine
Titan Pharmaceuticals (OTCQB: TTNP) said its development partner, Braeburn Pharmaceuticals, has resubmitted an NDA to the FDA for Probuphine, Titan’s subdermal implant containing buprenorphine HCl for...
View ArticleClik here to view.
HCW starts CymaBay Therapeutics at buy
H.C. Wainwright has initiated coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $12 price target, saying positive FDA guidance on potential labeling for arhalofenate, its lead drug...
View ArticleClik here to view.
Vital receives FDA guidance for Phase 3 trial
Vital Therapies (NASDAQ:VTL) has received written responses from the FDA to its Type C meeting request on the planned VTL-308 Phase 3 clinical trial. At the FDA’s suggestion, the company has...
View ArticleClik here to view.
Can-Fite submits Phase 3 protocol for RA study
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted its Phase 3 clinical study protocol to the Institutional Review Board of Barzilai Medical Center in Israel and will file similar submissions...
View ArticleClik here to view.
HCW starts Juniper Pharma at buy
H.C. Wainwright has started new coverage of Juniper Pharmaceuticals (NASDAQ:JNP) with a “buy” rating and $18 price target. The stock closed at $7.49 on Monday. Juniper is a specialty pharma company...
View ArticleClik here to view.
Dipexium Pharma receives Locilex patent in Japan
Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry...
View ArticleClik here to view.
Titan Pharma presents Phase 3 Probuphine data
Titan Pharmaceuticals (NASDAQ:TTNP) has presented data from the last Phase 3 study of Probuphine, a six month subdermal buprenorphine implant for the long-term maintenance treatment of opioid...
View ArticleClik here to view.
Rodman starts Presbia at buy
Rodman & Renshaw has initiated coverage of Presbia PLC (NASDAQ:LENS) with the “buy” rating and 18-month price target of $14. The stock closed at $3.90 on Tuesday. Presbia has a novel corneal inlay...
View ArticleClik here to view.
Leerink starts Theravance Biopharma at outperform
Leerink has initiated coverage of Theravance Biopharma (NASDAQ:TBPH) with an “outperform” rating and $26 price target. The stock closed at $18.10 on Wednesday. Theravance was formed in 2014 via a spin...
View ArticleClik here to view.
Dipexium completes enrollment in one Locilex Phase 3 trial
Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed the patient enrollment objective in the OneStep-2 Phase 3 clinical trial of its Locilex topical antibiotic peptide. The company’s OneStep-1 Phase 3...
View ArticleClik here to view.
Leerink downgrades Epirus Biopharma to market perform
Leerink Partners has downgraded Epirus Biopharmaceuticals (NASDAQ:PRS) to “market perform” from “outperform” and slashed its price target to 75 cents from $10. The stock closed at 78 cents on Friday....
View ArticleClik here to view.
Dipexium completes enrollment in second Phase 3 trial
Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed patient enrollment in the OneStep-1 pivotal Phase 3 clinical trial of its Locilex broad-spectrum, topical antibiotic peptide. Last week, the...
View ArticleClik here to view.
Oramed posts positive oral insulin Phase 2b results
Oramed Pharmaceuticals (NASDAQ:ORMP) has reported positive top-line results from its Phase 2b study, designed to evaluate the safety and efficacy of its oral insulin capsule, ORMD-0801, in patients...
View Article
